Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Neuromuscul Disord. 2015 May 27;25(9):699–705. doi: 10.1016/j.nmd.2015.05.008

Figure 3.

Figure 3

The effect of D156844 on changes in body mass of SMNΔ7 SMA mice being treated with recombinant follistatin. (A) Body mass curves of SMNΔ7 SMA mice (closed) and non-SMA mice (open) receiving 3 mg/kg/d D156844 and 1 mg/kg/qad follistatin (combo; circles) or vehicle (triangles). Treatment began at PND04. (B) Body mass curves of SMNΔ7 SMA mice (closed) and non-SMA mice (open) receiving 1 mg/kg/qad follistatin (circles) or vehicle (triangles). Treatment began at PND04. (C) Changes in body mass between PND04 and PND11 of SMNΔ7 SMA mice treated with either 3 mg/kg/d D156844 and 1 mg/kg/qad follistatin (combo), 3 mg/kg/d D156844, 1 mg/kg/qad follistatin or vehicle. The change in body mass between PND04 and PND11 of age-matched nonSMA littermates was also shown. The statistical significances for pairs of experimental groups were provided below the bar graph.